Dr Camille Esneau
Postdoctoral Researcher
School of Biomedical Sciences and Pharmacy
- Email:camille.esneau@newcastle.edu.au
- Phone:(02) 4042 0117
Career Summary
Biography
Camille Esneau is a post-doctoral researcher in virology, with a specific focus on respiratory virus diversity and host-pathogen interactions.
The focus of her research is to understand how virus diversity relates to the development of severe respiratory illnesses, in order to better develop antiviral therapies against those viruses.
Camille holds a PhD degree from University of Newcastle and is employed in A/Prof Nathan Bartlett's team as a post-doctoral researcher, working in collaboration with industry and other institutions Australia-wide. This includes participating in an ongoing collaboration with the Kirby Institute (University of New South Wales, Sydney) for which she was conferred an adjunct associate lecturer academic title.
Throughout her PhD and work experience, she has acquired extensive knowledge and skills working with different species of human pathogenic viruses (including class III pathogens such as SARS-CoV-2), notably using culture models of human airway epithelial cells (fully differentiated at air-liquid interface to reconstitute the structure of human airway epithelium) and molecular methods for virus detection.
Qualifications
- Doctor of Philosopy, University of Newcastle
- Bachelor of Science, Versailles Saint-Quentin-en-Yvelines University
- Master of Science, Versailles Saint-Quentin-en-Yvelines University
Keywords
- Respiratory viruses
- Virology
Languages
- French (Mother)
- English (Fluent)
Fields of Research
| Code | Description | Percentage |
|---|---|---|
| 310706 | Virology | 50 |
| 320103 | Respiratory diseases | 20 |
| 320407 | Innate immunity | 30 |
Professional Experience
UON Appointment
| Title | Organisation / Department |
|---|---|
| Postdoctoral Researcher | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Chapter (2 outputs)
| Year | Citation | Altmetrics | Link | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 |
Esneau C, Croft S, Loo SL, Ghildyal R, 'Rhinovirus diversity and virulence factors', Rhinovirus Infections: Rethinking the Impact on Human Health and Disease 25-59 (2019) The rhinovirus (RV) genus is highly diverse, consisting of three species and more than 167 subtypes, utilizing three different receptors for cell entry. This diversity has been an... [more] The rhinovirus (RV) genus is highly diverse, consisting of three species and more than 167 subtypes, utilizing three different receptors for cell entry. This diversity has been an obstacle to the development of effective cross-reactive antiviral treatments or vaccine strategies. Accumulating research suggests a possible association of virus species/subtypes with illness severity presenting the possibility for antiviral approaches targeting specific subtypes instead of all RVs. To facilitate such an approach, identification of the underlying molecular mechanism and the viral factor/s that mediate disease is required. Recent literature shows a clear species/subtype associated divergence in the host cell directed activity of RV proteases. Whether these differences correlate with the subtype-specific differences in illness severity remains to be confirmed. In this chapter, we bring together current knowledge of the association of RV species/subtypes with illness and explore the possible role of RV proteases as the main virulence factors associated with illness severity.
|
||||||||||
| 2019 |
Bartlett N, Esneau C, Bochkov Y, 'Rhinovirus structure, replication, and classification', Rhinovirus infections: Rethinking the impact on human health and disease, Elsevier, London 1-23 (2019) [B1]
|
Nova | |||||||||
Journal article (12 outputs)
| Year | Citation | Altmetrics | Link | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 |
Speck P, Mackenzie J, Bull RA, Slobedman B, Drummer H, Fraser J, et al., 'Statement in Support of: "Virology under the Microscope-a Call for Rational Discourse"', MBIO, 14 (2023)
|
||||||||||
| 2023 |
Speck P, Mackenzie J, Bull RA, Slobedman B, Drummer H, Fraser J, et al., 'Statement in Support of: "Virology under the Microscope-a Call for Rational Discourse"', MSPHERE, 8 (2023)
|
||||||||||
| 2023 |
Speck P, Mackenzie J, Bull RA, Slobedman B, Drummer H, Fraser J, et al., 'Statement in Support of: "Virology under the Microscope-a Call for Rational Discourse".', J Virol, 97 e0045123 (2023)
|
||||||||||
| 2023 |
Akerman A, Milogiannakis V, Jean T, Esneau C, Silva MR, Ison T, et al., 'Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.', EBioMedicine, 90 104545 (2023) [C1]
|
Nova | |||||||||
| 2022 |
Williams TC, Loo S-L, Nichol KS, Reid AT, Veerati PC, Esneau C, et al., 'IL-25 blockade augments antiviral immunity during respiratory virus infection', COMMUNICATIONS BIOLOGY, 5 (2022) [C1]
|
Nova | |||||||||
| 2022 |
Aggarwal A, Stella AO, Walker G, Akerman A, Esneau C, Milogiannakis V, et al., 'Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia', NATURE MICROBIOLOGY, 7 896-908 (2022) [C1]
|
Nova | |||||||||
| 2022 |
Esneau C, Duff AC, Bartlett NW, 'Understanding Rhinovirus Circulation and Impact on Illness', VIRUSES-BASEL, 14 (2022) [C1]
|
Nova | |||||||||
| 2022 |
George PM, Reed A, Desai SR, Devaraj A, Faiez TS, Laverty S, et al., 'A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae', SCIENCE TRANSLATIONAL MEDICINE, 14 (2022) [C1]
|
Nova | |||||||||
| 2021 |
Girkin J, Loo S-L, Esneau C, Maltby S, Mercuri F, Chua B, et al., 'TLR2-mediated innate immune priming boosts lung anti-viral immunity', EUROPEAN RESPIRATORY JOURNAL, 58 (2021) [C1]
|
Nova | |||||||||
| 2020 |
Loo SL, Wark PAB, Esneau C, Nichol KS, Hsu ACY, Bartlett NW, 'Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in differentiated primary human bronchial epithelial cells', American Journal of Physiology - Lung Cellular and Molecular Physiology, 319 L926-L931 (2020) [C1] The recurrent emergence of novel, pathogenic coronaviruses (CoVs) severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1; 2002), Middle East respiratory syndrome (MERS)-CoV (... [more] The recurrent emergence of novel, pathogenic coronaviruses (CoVs) severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1; 2002), Middle East respiratory syndrome (MERS)-CoV (2012), and most recently SARS-CoV-2 (2019) has highlighted the need for physiologically informative airway epithelial cell infection models for studying immunity to CoVs and development of antiviral therapies. To address this, we developed an in vitro infection model for two human coronaviruses; alphacoronavirus 229E-CoV (229E) and betacoronavirus OC43-CoV (OC43) in differentiated primary human bronchial epithelial cells (pBECs). Primary BECs from healthy subjects were grown at air-liquid interface (ALI) and infected with 229E or OC43, and replication kinetics and time-course expression of innate immune mediators were assessed. OC43 and 229E-CoVs replicated in differentiated pBECs but displayed distinct replication kinetics: 229E replicated rapidly with viral load peaking at 24 h postinfection, while OC43 replication was slower peaking at 96 h after infection. This was associated with diverse antiviral response profiles defined by increased expression of type I/III interferons and interferon-stimulated genes (ISGs) by 229E compared with no innate immune activation with OC43 infection. Understanding the host-virus interaction for previously established coronaviruses will give insight into pathogenic mechanisms underpinning SARS-CoV-2-induced respiratory disease and other future coronaviruses that may arise from zoonotic sources.
|
Nova | |||||||||
| 2019 |
Esneau C, Raynal B, Roblin P, Brule S, Richard C-A, Fix J, et al., 'Biochemical characterization of the respiratory syncytial virus N-0-P complex in solution', JOURNAL OF BIOLOGICAL CHEMISTRY, 294 3647-3660 (2019)
|
||||||||||
| 2018 |
Richard C-A, Rincheval V, Lassoued S, Fix J, Cardone C, Esneau C, et al., 'RSV hijacks cellular protein phosphatase 1 to regulate M2-1 phosphorylation and viral transcription', PLOS PATHOGENS, 14 (2018)
|
||||||||||
| Show 9 more journal articles | |||||||||||
Grants and Funding
Summary
| Number of grants | 1 |
|---|---|
| Total funding | $4,949 |
Click on a grant title below to expand the full details for that specific grant.
20231 grants / $4,949
Improving arbovirus surveillance in the Hunter region through the development of PCR based assay to survey mosquito species and arboviruses.$4,949
Funding body: University of Newcastle
| Funding body | University of Newcastle |
|---|---|
| Project Team | Doctor Camille Esneau, Professor Nathan Bartlett, Doctor Toby Mills |
| Scheme | Pilot Funding Scheme |
| Role | Lead |
| Funding Start | 2023 |
| Funding Finish | 2023 |
| GNo | G2300473 |
| Type Of Funding | Internal |
| Category | INTE |
| UON | Y |
Dr Camille Esneau
Position
Postdoctoral Researcher
Bartlett Team
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing
Contact Details
| camille.esneau@newcastle.edu.au | |
| Phone | (02) 4042 0117 |
Office
| Building | HMRI - L2E |
|---|
